Literature DB >> 27473027

Erythropoietin attenuates motor impairments induced by bilateral renal ischemia/reperfusion in rats.

Mahshid Tahamtan1, Seyed M S Moosavi2, Vahid Sheibani1, Mohsen Nayebpour3, Saeed Esmaeili-Mahani1,4, Mohammad Shabani1.   

Abstract

Neurologic sequelae remain a common and destructive problem in patients with acute kidney injury. The objective of this study was to evaluate the possible neuroprotective effect of erythropoietin (EPO) on motor impairments following bilateral renal ischemia (BRI) in two time points after reperfusion: short term (24 h) and long term (1 week). Male Wistar rats underwent BRI or sham surgery. EPO or saline administration was performed 30 min before surgery (1000 U/kg, i.p.). Explorative behaviors and motor function of the rats were evaluated by open field, rotarod, and wire grip tests. Plasma concentrations of blood urea nitrogen (BUN) and creatinine (Cr) were significantly enhanced in BRI rats 24 h after reperfusion. BRI group had only an increased level of BUN but not Cr 1 week after reperfusion. Impairment of balance function by BRI was not reversed by EPO 24 h after reperfusion, but counteracted 7 days after renal ischemia. Muscle strength had no significant differences between the groups. BRI group had a decrease in locomotor activity, and EPO could not reverse this reduction in both time points of the experiment. Although EPO could not be offered as a potential neuroprotective agent in the treatment of motor dysfunctions induced by BRI, it could be effective against balance dysfunction 1 week after renal ischemia.
© 2016 Société Française de Pharmacologie et de Thérapeutique.

Entities:  

Keywords:  erythropoietin; motor impairments; neuroprotective; renal ischemia

Mesh:

Substances:

Year:  2016        PMID: 27473027     DOI: 10.1111/fcp.12226

Source DB:  PubMed          Journal:  Fundam Clin Pharmacol        ISSN: 0767-3981            Impact factor:   2.748


  4 in total

1.  Pre-Treatment with Erythropoietin Attenuates Bilateral Renal Ischemia-Induced Cognitive Impairments.

Authors:  Mahshid Tahamtan; Vahid Sheibani; Seyed Mostafa Shid Moosavi; Majid Asadi-Shekaari; Saeed Esmaeili-Mahani; Iraj Aghaei; Mohammad Shabani
Journal:  Iran J Pharm Res       Date:  2018       Impact factor: 1.696

Review 2.  Uremic Sarcopenia: Clinical Evidence and Basic Experimental Approach.

Authors:  Hiroshi Nishi; Koji Takemura; Takaaki Higashihara; Reiko Inagi
Journal:  Nutrients       Date:  2020-06-18       Impact factor: 5.717

3.  Renoprotective potential of exogen erythropoietin on experimental ruptured abdominal aortic aneurysm model: An animal study.

Authors:  Gokalp Altun; Yavuz Cakiroglu; Zerrin Pulathan; Esin Yulug; Ahmet Mentese
Journal:  Iran J Basic Med Sci       Date:  2020-02       Impact factor: 2.699

4.  Erythropoietin attenuates motor neuron programmed cell death in a burn animal model.

Authors:  Sheng-Hua Wu; I-Cheng Lu; Su-Shin Lee; Aij-Lie Kwan; Chee-Yin Chai; Shu-Hung Huang
Journal:  PLoS One       Date:  2018-01-31       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.